{"id":141053,"date":"2024-12-04T16:44:00","date_gmt":"2024-12-04T21:44:00","guid":{"rendered":"https:\/\/www.bumc.bu.edu\/camed\/?post_type=bu-article&p=141053"},"modified":"2026-01-19T11:42:23","modified_gmt":"2026-01-19T16:42:23","slug":"revisiting-vitamin-d-guidelines","status":"publish","type":"bu-article","link":"https:\/\/www.bumc.bu.edu\/camed\/news-events\/articles\/2024\/revisiting-vitamin-d-guidelines\/","title":{"rendered":"Revisiting Vitamin D Guidelines"},"content":{"rendered":"\t
\n\t\t
\n\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\"Bottle\n\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t

Photo by Maria Kozyr<\/a> on Unsplash<\/a><\/p>\n\t\t\t\n\n\t\t\t\n\t\t\t\t

\n\n\t\t\t\t\t\n\t\t\t\t\t
\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t\tResearch<\/span>\n\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tRevisiting Vitamin D Guidelines\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/h1>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\n\t\t\t\t<\/div>\n\n\t\t\t\n\t\t<\/div>\n\n\t\t\n\t<\/div>\n\n\t\n
\n\t
\n\t\t\t\t\t
December 4, 2024<\/div>\n\t\t\n\t\t\t\t
\n\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\tTwitter<\/span><\/span>\n\t\t\tFacebook<\/span><\/span>\n\t\t\t<\/span>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\t\n\n\n

In June of 2024, the Endocrine Society, influenced by a substantial body of research conducted in recent years, published new clinical practice guidelines for the testing and supplementation of Vitamin D for the prevention of disease. These new recommendations included limiting vitamin D supplementation beyond the daily recommended intake to specific risk groups and advised against routine 25-hydroxyvitamin D [25(OH)D] testing in healthy individuals.<\/p>\n\n\n\n

\"head
Michael Holick<\/figcaption><\/figure><\/div>\n\n\n\n

In a new review article<\/a> in the journal, Endocrine Practice, Michael Holick<\/a>, PhD, MD, professor of medicine, pharmacology, physiology & biophysics and molecular medicine at Boston University Chobanian & Avedisian School of Medicine, compares and contrasts the 2024 Endocrine Society\u2019s Clinical Guidelines on Vitamin D with those he helped design in 2011.<\/p>\n\n\n\n

\u201cThe 2011 guidelines provided clinicians with guidance for how to evaluate and treat patients with vitamin D deficiency and prevent recurrence, whereas the 2024 guidelines made recommendations for the general healthy population for skeletal and extra skeletal health benefits of vitamin D. I believe this will cause great confusion for physicians and health care professionals as to how to determine if their patient who is at risk for vitamin D deficiency is vitamin D deficient since screening children and adults for their vitamin D status is not recommended in the new guidelines,\u201d explains Holick.<\/p>\n\n\n\n

Among the major differences:<\/p>\n\n\n\n